Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corcept Therapeutics

74.45
-4.9200-6.20%
Post-market: 74.42-0.0300-0.04%19:38 EDT
Volume:2.54M
Turnover:189.32M
Market Cap:7.85B
PE:60.53
High:78.00
Open:77.60
Low:72.59
Close:79.37
Loading ...

SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug

Zacks
·
27 Mar

3 Reasons to Sell CORT and 1 Stock to Buy Instead

StockStory
·
27 Mar

Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year?

Zacks
·
21 Mar

3 Growth Stocks in Hot Water

StockStory
·
19 Mar

AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies

Zacks
·
17 Mar

NVO Stock Down 9% as CagriSema Misses Target in Second Obesity Study

Zacks
·
12 Mar

INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies

Zacks
·
10 Mar

Corcept Therapeutics Initiates Momentum Trial to Determine Prevalence of Hypercortisolism in Patients With Resistant Hypertension

THOMSON REUTERS
·
10 Mar

Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

Business Wire
·
10 Mar

Corcept Shares Rise More Than 55% in 6 Months: Here's Why

Zacks
·
07 Mar

Are Options Traders Betting on a Big Move in Corcept Therapeutics (CORT) Stock?

Zacks
·
07 Mar

Stock Track | Corcept Therapeutics Plummets 5.03% as Full-Year and Q4 Earnings Disappoint

Stock Track
·
05 Mar

Truist Financial Keeps Their Buy Rating on Corcept Therapeutics (CORT)

TIPRANKS
·
04 Mar

Corcept Therapeutics: Strong Buy Rating Driven by NDA Acceptance and Promising Trial Outcomes

TIPRANKS
·
04 Mar

Corcept Therapeutics Full Year 2024 Earnings: Misses Expectations

Simply Wall St.
·
04 Mar

Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers

StockStory
·
04 Mar

FDA files Corcept’s NDA for Relacorilant as treatment in Hypercortisolism

TIPRANKS
·
04 Mar

BRIEF-FDA Files Corcept’s New Drug Application For Relacorilant As Treatment For Patients With Hypercortisolism

Reuters
·
04 Mar

FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

THOMSON REUTERS
·
04 Mar

FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

Business Wire
·
04 Mar